ELECTRON MICROSCOPIC CHARACTERIZATION OF THE DYNAMICS OF SCIATIC NERVE DAMAGE IN RATS WITH CISPLATIN- AND PACLITAXEL-INDUCED NEUROTOXICITY

Authors:

Abstract:

Chemotherapy-induced peripheral neuropathy limits the efficacy of cisplatin and paclitaxel in cancer treatment. This study characterized ultrastructural changes in the rat sciatic nerve on days 14 and 28 post-administration using transmission electron microscopy. Adult male inbred rats (n=30/group) were divided into three groups: paclitaxel (2 mg/kg i.p., 4 injections every other day, total 8 mg/kg), cisplatin (2 mg/kg i.p., twice weekly for 4 weeks, total 16 mg/kg), and combined treatment (cisplatin 2 mg/kg i.p. at 37°C+paclitaxel 5 mg/kg i.v. weekly for 6 weeks; total cisplatin 12 mg/kg, paclitaxel 30 mg/kg). Nerve fragments were fixed in 2°% osmium tetroxide, embedded in Epon/Araldite, and examined at ×4800–×16000. Cisplatin induced more severe degeneration than paclitaxel, including myelin destruction, axonal degeneration, and neuroglio-vascular swelling. Damage progressed from day 14 to 28, revealing cumulative toxicity. Combined administration exerted synergistic effects, disrupting the entire neuro-glio-vascular unit. Endothelial dysfunction emerged as the primary trigger. These findings underscore the multifactorial nature of CIPN and the need for early neuroprotective interventions targeting vascular stability and mitochondrial homeostasis. Basement membrane thickness increased from 158±19 nm (day 14, paclitaxel group) to 268±31 nm on day 28 in the combined treatment group.

Keywords:

chemotherapy-induced peripheral neuropathy cisplatin paclitaxel sciatic nerve ultrastructure electron microscopy rats

References:

1. Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Br J Anaesth. 2017 Oct;119(4):737–49. DOI:10.1093/bja/aex229.
2. Fukuda Y, Li Y, Segal RA. A Mechanistic Understanding of Axon Degeneration in Chemotherapy-Induced Peripheral Neuropathy. Front Neurosci. 2017 Aug 31;11. DOI:10.3389/fnins.2017.00481.
3. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;1;14(4):iv45–54. DOI:10.1093/neuonc/nos203.
4. Joseph EK, Chen X, Bogen O, Levine JD. Oxaliplatin Acts on IB4-Positive Nociceptors to Induce an Oxidative Stress-Dependent Acute Painful Peripheral Neuropathy. J Pain. 2008 May;9(5):463–72. DOI:10.1016/j.jpain.2008.01.335.
5. Kotvytska AA, Tykhonovych K V, Kryvoruchko TD, Neporada KS, Beregovyi SM. Paclitaxel-induced neuropathy induces changes in oral cavity organs of rats. Regul Mech Biosyst. 2023 Feb 7;14(1):102–5. DOI:10.15421/022315.
6. Kotyk T, Varkey TC, Demydchuk A, Shamalo S, Tokaruk N, Bedei V, et al. Morphometrical analysis of myelinated nerve fibers: is there a room for improvement? Anat Sci Int. 2025 Mar 10;100(2):191–7. DOI:10.1007/s12565-024-00801-6.
7. Li B, Jia S, Yue T, Yang L, Huang C, Verkhratsky A, et al. Biphasic Regulation of Caveolin-1 Gene Expression by Fluoxetine in Astrocytes: Opposite Effects of PI3K/AKT and MAPK/ERK Signaling Pathways on c-fos. Front Cell Neurosci. 2017 Oct 31;11. DOI:10.3389/fncel.2017.00335.
8. Mattar M, Umutoni F, Hassan MA, Wamburu MW, Turner R, Patton JS, et al. Chemotherapy-Induced Peripheral Neuropathy: A Recent Update on Pathophysiology and Treatment. Life. 2024;14(8):991. DOI:10.3390/LIFE14080991 Available from: https://www.mdpi.com/2075-1729/14/8/991/htm.
9. Melli G, Taiana M, Camozzi F, Triolo D, Podini P, Quattrini A, et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol. 2008;214(2):276–84. DOI:10.1016/j.expneurol.2008.08.013.
10. Ostrovskyi M. Morphological manifestations of experimental paclitaxel-induced sciatic neuropathy under correction of 2-ethyl-6-methyl-3-hydroxypyridine succinate. ScienceRise: Medical Science [Internet]. 2021;3(3(42)):20–6. DOI:10.15587/2519-4798.2021.232975 Available from: https://journals.uran.ua/sr_med/article/view/232975.
11. Takeuchi H, Jin S, Suzuki H, Doi Y, Liang J, Kawanokuchi J, et al. Blockade of microglial glutamate release protects against ischemic brain injury. Exp Neurol. 2008;214(1):144–6. DOI:10.1016/j.expneurol.2008.08.001.
12. Tykhonovych KV, Neporada KS, Yeroshenko GA. Pathomorphological changes in salivary glands of rats under the condition of diabetic neuropathy and correction. World of Medicine and Biology. 2023;19(83):229. DOI:10.26724/2079-8334-2023-1-83-229-232.
13. Vermeer CJC, Hiensch AE, Cleenewerk L, May AM, Eijkelkamp N. Neuro-immune interactions in paclitaxel-induced peripheral neuropathy. Acta Oncol (Madr). 2025;60(10):1369–82. DOI:10.1080/0284186X.2021.1954241 Available from: https://www.tandfonline.com/doi/abs/10.1080/0284186X.2021.1954241.
14. Xiao WH, Zheng H, Zheng FY, Nuydens R, Meert TF, Bennett GJ. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience. 2011 Dec;199:461–9. DOI:10.1016/j.neuroscience.2011.10.010.
15. Yamamoto S, Egashira N. Drug Repositioning for the Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Mechanism- and Screening-Based Strategy. Front Pharmacol. 2021 Jan 14;11. DOI:10.3389/fphar.2020.607780.

Publication:

«World of Medicine and Biology» Vol. 21 No. 94 (2025) , с. 195-200
УДК 616.833-009.17-092.9:615.277.3

DOI:

https://doi.org/10.26724/2079-8334-2025-4-94-195-200